GlassScriptPhysician profile
Daryl L Mcdaniel
NPI 1790754190
$4,355.04
in general payments reported to CMS, 2019-2025
27 companies · $1,041 in 2025
The $1,041 reported for 2025 was more than what a typical Glaucoma Specialist provider received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $493 · 2020: $255 · 2021: $605 · 2022: $280 · 2023: $610 · 2024: $1,072 · 2025: $1,041.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,176 · Travel and Lodging: $519 · Honoraria: $27.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,176.04 |
| Travel and Lodging | $519.02 |
| Honoraria | $27.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,283.45 | 2019-2025 | Wavelight Refractive Suite, Clareon, Argos |
| Abbvie INC. | $559.93 | 2022-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $294.33 | 2019-2025 | Tecnis Iol, Veritas Vision System |
| Beaver-Visitec International, INC. | $274.91 | 2020-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $169.76 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $167.40 | 2021-2025 | Acthar |
| Glaukos Corporation | $166.18 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $139.62 | 2019-2023 | |
| Ivantis, INC | $117.68 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $114.18 | 2025 | Syfovre |
| Bausch & Lomb Americas INC. | $108.88 | 2024-2025 | Xipere, Miebo, Xiidra |
| Allergan, INC. | $107.91 | 2020-2021 | |
| Ocular Therapeutix, INC. | $95.32 | 2024-2025 | Dextenza |
| Astellas Pharma Global Development | $92.08 | 2025 | Izervay |
| Rxsight INC | $89.97 | 2024-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| New World Medical,INC. | $87.99 | 2019-2022 | |
| Carl Zeiss Meditec USA, INC. | $85.30 | 2021-2023 | Quatera 700 |
| Tarsus Pharmaceuticals, INC. | $72.41 | 2024-2025 | Xdemvy |
| Genentech, INC. | $65.01 | 2025 | Vabysmo |
| Regeneron Pharmaceuticals, INC. | $59.05 | 2025 | Eylea Hd |
| Dompe US, INC. | $57.73 | 2024-2025 | Oxervate |
| Thea Pharma INC. | $43.89 | 2025 | Iyuzeh |
| Aerie Pharmaceuticals, INC. | $34.32 | 2019 | |
| Horizon Therapeutics Plc | $24.65 | 2023 | Tepezza |
| Biotissue Holdings INC. | $19.00 | 2025 | |
| Rayner Intraocular Lenses Limited | $12.74 | 2023 | Omidria, Rayone Aspheric, Rayone Emv |
| Sight Sciences, INC. | $11.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daryl Mcdaniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.